Last update:

Oncology & Cancer news

Oncology & Cancer

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

Oncology & Cancer

'Explant' technique predicts a tumor's responsiveness to breast cancer treatment

Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer patients will respond to chemotherapy and antibody-directed cancer treatments.

Medications

New drug for prostate cancer patients in clinical trials

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical ...

Medications

Talquetamab plus teclistamab shows promise in multiple myeloma

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according ...

Oncology & Cancer

New tool puts reproductive risk for BRCA carriers into perspective

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA). Maxwell met her at a conference ...

Oncology & Cancer

Study identifies TBK1 as key to overcoming CAR T resistance

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author ...

Oncology & Cancer

Extrachromosomal DNA could be a target of future cancer therapies

Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher concentration of a specific kind of DNA—extrachromosomal or ecDNA—in more aggressive and advanced ...

Oncology & Cancer

Immune signatures may predict adverse events from immunotherapy

Distinct immune "signatures" in patients who develop adverse events while receiving immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a ...

Oncology & Cancer

The importance of breast cancer screening

October is Breast Cancer Awareness Month. Breast cancer is the second-leading cause of cancer deaths in women across the U.S. And rates of the disease continue to climb, notably among younger women. A report from the American ...

Oncology & Cancer

Promising treatment for gastrointestinal stromal tumors

About 1,200 Germans are diagnosed with gastrointestinal stromal tumors every year—a rare type of cancer in which the tumors develop in the walls of the digestive organs and quickly develop resistance to common precision ...

Oncology & Cancer

Clinical trials confirm zolbetuximab's efficacy in gastric cancer

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of tumor-related deaths. This is due to late diagnosis and the rapid spread of tumor cells throughout ...

Oncology & Cancer

An AI-powered pipeline for personalized cancer vaccines

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses ...